Ascendis Pharma A/S (NASDAQ:ASND) Trading Down 4.6% - Time to Sell?

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s share price dropped 4.6% during trading on Wednesday . The stock traded as low as $128.41 and last traded at $125.07. Approximately 13,803 shares were traded during trading, a decline of 97% from the average daily volume of 420,233 shares. The stock had previously closed at $131.06.

Analyst Ratings Changes

ASND has been the subject of a number of research analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, November 15th. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Wedbush reissued an "outperform" rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. UBS Group started coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Finally, Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $192.07.

Ascendis Pharma A/S Price Performance

The firm has a market capitalization of $7.72 billion, a P/E ratio of -15.74 and a beta of 0.65. The firm's fifty day moving average price is $133.19 and its 200-day moving average price is $133.40.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $30,000. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter valued at $60,000. Blue Trust Inc. lifted its holdings in shares of Ascendis Pharma A/S by 540.5% in the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after purchasing an additional 427 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after buying an additional 214 shares during the period. Finally, Signaturefd LLC grew its holdings in shares of Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after buying an additional 80 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.